Simbrinza · DIN 02435411 · 1.0% & 0.2% · Oph suspension-10mL Pk
Limited Use, Reason for Use code 466, 393 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 466, 393 required
Write on scriptone applicable Reason for Use code, 466 or 393 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 466, 393
Reason for Use code 466
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with brinzolamide or brimonidine.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Simbrinza · DIN 02435411
Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-10-29
Health Canada: Marketed since 2018-04-18 · brand SIMBRINZA · ATC S01EC54 BRINZOLAMIDE, COMBINATIONS · form Suspension · route Ophthalmic · ingredients BRINZOLAMIDE 1 %/W/V, BRIMONIDINE TARTRATE 0.2 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Simbrinza: Formulary list price $50.69 per unit (the source does not state the unit; exact figure $50.6900). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435411)
Source record
DIN 02435411: Simbrinza
Raw flags: sec12=Y, sec3=Y
Item: 523600143; group id 617; item number 1584; lccId 00258; manufacturer id NOV
Source form: Oph Susp-10mL Pk; strength: 1.0% & 0.2%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $50.6900; ministry $50.6900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435411
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91973
Shortage status: not checked (no credentials)